Cardio-oncology, novel biomarkers, and advances in structural heart disease and arrhythmia management

Scritto il 21/07/2026
da Patrizio Lancellotti

Acta Cardiol. 2026 Jul 21:1-7. doi: 10.1080/00015385.2026.2705730. Online ahead of print.

ABSTRACT

Cardiovascular medicine continues to move towards precision-based, individualised patient care, supported by novel biomarkers, refined imaging protocols, and multidisciplinary risk assessment. The studies featured in this issue of Acta Cardiologica span cardio-oncology, structural heart disease, immune and proteomic biomarkers, sepsis-related cardiac dysfunction, arrhythmia management, and vascular disease. Collectively, they underscore the growing importance of individualised diagnostic and therapeutic strategies across the cardiovascular spectrum, from cancer-related heart failure to conduction system pacing and cardiac arrest prevention.

PMID:42480041 | DOI:10.1080/00015385.2026.2705730